Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
Jamshidi A, Gharibdoost F, Vojdanian M, Soroosh SG, Soroush M, Ahmadzadeh A, Nazarinia MA, Mousavi M, Karimzadeh H, Shakibi MR, Rezaieyazdi Z, Sahebari M, Hajiabbasi A, Ebrahimi AA, Mahjourian N, Rashti AM. Jamshidi A, et al. Among authors: ahmadzadeh a. Arthritis Res Ther. 2017 Jul 20;19(1):168. doi: 10.1186/s13075-017-1371-4. Arthritis Res Ther. 2017. PMID: 28728599 Free PMC article. Clinical Trial.
International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients.
Rezaieyazdi Z, Farooqi A, Soleymani-Salehabadi H, Ahmadzadeh A, Aslani M, Omidian S, Sadoughi A, Vahidi Z, Khodashahi M, Zamurrad S, Mortazavi-Jahromi SS, Fallahzadeh H, Hosseini M, Aghazadeh Z, Ekhtiari P, Matsuo H, Rehm BHA, Cuzzocrea S, D'Aniello A, Mirshafiey A. Rezaieyazdi Z, et al. Among authors: ahmadzadeh a. Inflammopharmacology. 2019 Oct;27(5):911-921. doi: 10.1007/s10787-018-00557-2. Epub 2019 Jan 2. Inflammopharmacology. 2019. PMID: 30604197 Clinical Trial.
Immunopharmacological effect of β-d-mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR-155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients.
Mortazavi-Jahromi SS, Aslani M, Omidian S, Ahmadzadeh A, Rezaieyazdi Z, Mirshafiey A. Mortazavi-Jahromi SS, et al. Among authors: ahmadzadeh a. Drug Dev Res. 2020 May;81(3):295-304. doi: 10.1002/ddr.21619. Epub 2019 Nov 1. Drug Dev Res. 2020. PMID: 31675124 Clinical Trial.
The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients.
Aslani M, Ahmadzadeh A, Rezaieyazdi Z, Mortazavi-Jahromi SS, Barati A, Hosseini M, Mirshafiey A. Aslani M, et al. Among authors: ahmadzadeh a. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):69-77. doi: 10.2174/1872213X13666191114111822. Recent Pat Inflamm Allergy Drug Discov. 2020. PMID: 31729947 Free PMC article.
The role of β-d-mannuronic acid, as a new non-steroidal anti-inflammatory drug on expression of miR-146a, IRAK1, TRAF6, NF-κB and pro-inflammatory cytokines following a clinical trial in rheumatoid arthritis patients.
Mortazavi-Jahromi SS, Ahmadzadeh A, Rezaieyazdi Z, Aslani M, Omidian S, Mirshafiey A. Mortazavi-Jahromi SS, et al. Among authors: ahmadzadeh a. Immunopharmacol Immunotoxicol. 2020 Jun;42(3):228-236. doi: 10.1080/08923973.2020.1742734. Epub 2020 Mar 29. Immunopharmacol Immunotoxicol. 2020. PMID: 32223462 Clinical Trial.
187 results